Comprehensive Evaluation of Plasma 7-Ketocholesterol and Cholestan-3β,5α,6β-Triol in an Italian Cohort of Patients Affected by Niemann-Pick Disease due to *NPC1* and *SMPD1* Mutations

Milena Romanello, Stefania Zampieri, Nadia Bortolotti, Laura Deroma, Annalisa Sechi, Agata Fiumara, Rossella Parini, Barbara Borroni, Francesco Brancati, Amalia Bruni, Cinzia V. Russo, Andrea Bordugo, Bruno Bembi, Andrea Dardis

PII: S0009-8981(16)30003-1
DOI: doi: 10.1016/j.cca.2016.01.003
Reference: CCA 14236

To appear in: *Clinica Chimica Acta*

Received date: 23 October 2015
Revised date: 24 November 2015
Accepted date: 4 January 2016

Comprehensive Evaluation of Plasma 7-Ketocholesterol and Cholestan-3β,5α,6β-Triol in an Italian Cohort of Patients Affected by Niemann-Pick Disease Due to *NPC1* and *SMPD1* Mutations.

Milena Romanello[a], Stefania Zampieri[a], Nadia Bortolotti[b], Laura Deroma[a], Annalisa Sechi[a], Agata Fiumara[c], Rossella Parini[d], Barbara Borroni[e], Francesco Brancati[f], Amalia Bruni[g], Cinzia V. Russo[h], Andrea Bordugo[i], Bruno Bembi[a], Andrea Dardis[a,*].

a. Regional Coordinator Centre for Rare Diseases, University Hospital Santa Maria della Misericordia, Udine, Italy.

b. Clinical Pathology Institute, University Hospital Santa Maria della Misericordia, Udine, Italy.

c. Department of Pediatrics, Regional Referral Center for Inherited Metabolic Disease, University of Catania, Catania, Italy.

d. Rare Metabolic Diseases Unit, Pediatric Clinic, San Gerardo Hospital, Monza, Italy.

e. Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy.

f. Medical Genetics Unit, Tor Vergata University, Roma, Italy.

g. Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy.

h. Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Naples, Italy.

i. Regional Centre for Newborn Screening, Diagnosis and Treatment of Inherited Metabolic Disorders and Inherited Metabolic Diseases Unit, Department of Pediatrics, Verona, Italy.

*Corresponding author:

E-mail: dardis.andrea@aoud.sanita.fvg.it (AD)

Abbreviations

3β,5α,6β-triol: cholestan-3β,5α,6β-triol**;** 3β,5α,6β-triol-DMG_2: bis-(dimethylglycinate)-derivative of 3β,5α,6β-triol**;** 7-KC: 7-ketocholesterol; [$^2H_7$]-7-KC: 25,26,26,26,27,27,27-[$^2H_7$]-7-ketocholesterol; [$^2H_7$]-3β,5α,6β -triol: 25,26,26,26,27,27,27-[$^2H_7$] cholestan-3β,5α,6β -triol ; APCI: atmospheric pressure chemical ionization**;** CE: collision energy**;** QC: quality control**;** CXP: collision cell exit potential**;** DMAP: 4-(dimethylamino) pyridine**;** DMG: dimethylglycine hydrochloride**;** DP: declustering potential**;** EDC: N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride**;** EP: entrance potential**;** IQR: interquartile range**;** KC-DMG: mono-dimethylglycinate-derivative of 7-KC**;** LLOQ: lower limit of quantification**;** LOD: limit of detection**;** LQC, MQC, HQC: low, medium and high plasma quality control respectively**;** Methanol-d_4: tetradeuteromethanol**;** TCA: tricholoroacetic acid**;** ULOQ: upper limit of quantification